ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--CyanVac LLC, a clinical-stage biotechnology company developing intranasal vaccines using a transformational parainfluenza virus 5 (PIV5)-based vector, ...
Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...
Even before the World Health Organization declared the COVID-19 outbreak a pandemic on March 11, 2020, the scientific community was mobilizing to develop vaccines with the hope of protecting us all.
Bayer's agrochemicals unit Monsanto has filed lawsuits in the US against the manufacturers of mRNA-based COVID-19 vaccines, claiming that they used its patent-protected technology in their products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback